Segment Information (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2022

Dec. 31, 2021

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ended March 31, 2022 and 2021 is as follows:

	Three Months Ended March 31, 2022
	Cell Therapy			BioBanking			Degenerative Disease		Other					Total
Net sales	$			$	1,283		$	4,652	$	—				$	5,935
Gross profit		—			335			1,574		—					1,909
Direct expenses		21,213			626			1,459		13,270					36,568
Segment contribution		(21,213	)		(291	)		115		(13,270	)				(34,659	)
Indirect expenses										6,955		(c	)		6,955
Loss from operations														$	(41,614	)
(c) Components of other
Change in fair value of contingent consideration liability										4,849
Change in fair value of contingent stock consideration										1,565
Amortization										541
Total other									$	6,955

	Three Months Ended March 31, 2021
	Cell Therapy			BioBanking		Degenerative Disease			Other					Total
Net sales	$	—		$	1,264	$	1,396		$	—				$	2,660
Gross profit		—			540		878			—					1,418
Direct expenses		16,287			252		2,014			6,063					24,616
Segment contribution		(16,287	)		288		(1,136	)		(6,063	)				(23,198	)
Indirect expenses										21,197		(d	)		21,197
Loss from operations														$	(44,395	)
(d) Components of other
Change in fair value of contingent consideration liability										20,656
Impairment of acquired intangible assets										—
Amortization										541
Total other									$	21,197

Financial information by segment is as follows:

	Year Ended December 31, 2021
	Cell Therapy			BioBanking			Degenerative Disease		Other			Total
Net revenues	$	—		$	5,522		$	15,813	$	—		$	21,335
Gross profit		—			1,873			9,809		—			11,682
Direct expenses		85,107			2,119			8,450		64,017			159,693
Segment contribution		(85,107	)		(246	)		1,359		(64,017	)		(148,011	)
Indirect expenses										(38,953	)(a)	$	(38,953	)
Loss from operations													(109,058	)
(a) Components of other
Change in fair value of contingent consideration liability										(41,145	)
Amortization										2,192
Total other									$	(38,953	)

	Year Ended December 31, 2020
	Cell Therapy			BioBanking		Degenerative Disease			Other			Total
Net revenues	$	—		$	5,556	$	8,722		$	—		$	14,278
Gross profit		—			3,262		6,084			—			9,346
Direct expenses		51,470			1,653		10,348			20,573			84,043
Segment contribution		(51,470	)		1,609		(4,264	)		(20,573	)		(74,697	)
Indirect expenses										77,228	(a)	$	77,228
Loss from operations													(151,925	)
(a) Components of other
Change in fair value of contingent consideration liability										(55,566	)
Impairment of acquired intangible assets										129,400
Amortization										3,394
Total other									$	77,228